Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo.
about
Progress and problems with the use of suicide genes for targeted cancer therapyThe engineered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of cancerTurning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate.Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.Cell fate control gene therapy based on engineered variants of human deoxycytidine kinaseGenetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems.The roles of macrophages and nitric oxide in interleukin-3-enhanced HSV-Sr39tk-mediated prodrug therapySitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma.Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.Conditional control of suicide gene expression in tumor cells with theophylline-responsive ribozyme.Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer.Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes.Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy.
P2860
Q28262370-64D1AE1C-D4B2-44FC-A0DD-471310DBA989Q30689378-82FBA377-F993-48B9-B337-18939A7FACBFQ34781094-C6DFF8B0-C68C-491F-8320-A178A80FEBDCQ35613655-A9B38B74-E5EF-425B-961F-438D251335D9Q35939470-BAB8A557-DEFB-4274-A34C-EE5C740D3EB0Q36592690-FEB6D970-DC30-4D83-A1E7-94EFB11E2F25Q36618550-3B736E3B-693D-4D4F-9D96-8C7367E491D9Q37818222-736BCDC6-7A75-4891-8F57-6EA913C079C8Q37989984-4FBCCED7-2DAB-4A61-802C-629166C373D0Q38792076-8E0C1808-4F36-49C9-AB0F-8D0BA4E94B82Q39386066-4E698121-6B65-46B6-BCE2-E77CDFF2903DQ39413034-EFE603C2-97C7-4B5E-857A-83FFB6959F0DQ41882677-999B120C-6767-4E2E-BA82-F683EE7DCB8A
P2860
Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Fusion enzymes containing HSV- ...... sitivity in vitro and in vivo.
@ast
Fusion enzymes containing HSV- ...... sitivity in vitro and in vivo.
@en
type
label
Fusion enzymes containing HSV- ...... sitivity in vitro and in vivo.
@ast
Fusion enzymes containing HSV- ...... sitivity in vitro and in vivo.
@en
prefLabel
Fusion enzymes containing HSV- ...... sitivity in vitro and in vivo.
@ast
Fusion enzymes containing HSV- ...... sitivity in vitro and in vivo.
@en
P2093
P2860
P356
P1433
P1476
Fusion enzymes containing HSV- ...... sitivity in vitro and in vivo.
@en
P2093
M Sanchez-Bonilla
P2860
P2888
P356
10.1038/CGT.2009.60
P577
2009-09-18T00:00:00Z